pramipexole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2233	104632-26-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: pramipexole hydrochloride pramipexole hydrochloride hydrate sifrol oprymea pramipexole (S)-Pramipexole mirapexin pramipexole dihydrochloride pramipexole dihydrochloride monohydrate pramipexole HCl pramipexol dihydrobromide	A dopamine agonist that binds with high selectivity and specificity to the D2 subfamily of dopamine receptors of which it has a preferential affinity to D3 receptors, and has full intrinsic activity. Pramipexole alleviates parkinsonian motor deficits by stimulation of dopamine receptors in the striatum. Animal studies have shown that pramipexole inhibits dopamine synthesis, release, and turnover. Molecular weight: 211.33 Formula: C10H17N3S CLOGP: 1.47 LIPINSKI: 0 HAC: 3 HDO: 2 TPSA: 50.94 ALOGS: -3.18 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

pramipexole hydrochloride
pramipexole hydrochloride hydrate
sifrol
oprymea
pramipexole
(S)-Pramipexole
mirapexin
pramipexole dihydrochloride
pramipexole dihydrochloride monohydrate
pramipexole HCl
pramipexol dihydrobromide

A dopamine agonist that binds with high selectivity and specificity to the D2 subfamily of dopamine receptors of which it has a preferential affinity to D3 receptors, and has full intrinsic activity. Pramipexole alleviates parkinsonian motor deficits by stimulation of dopamine receptors in the striatum. Animal studies have shown that pramipexole inhibits dopamine synthesis, release, and turnover.

Molecular weight: 211.33
Formula: C10H17N3S
CLOGP: 1.47
LIPINSKI: 0
HAC: 3
HDO: 2
TPSA: 50.94
ALOGS: -3.18
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2.50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.20 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	90 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.30 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	93 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	7 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	7.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.85 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	12.40 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
July 1, 1997	FDA	BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Gambling disorder	419.43	11.47	104	28872	1090	50575058
Dyskinesia	360.85	11.47	215	28761	27646	50548502
Impulse-control disorder	315.88	11.47	74	28902	596	50575552
Compulsive shopping	279.86	11.47	68	28908	650	50575498
On and off phenomenon	252.12	11.47	72	28904	1340	50574808
Hallucination	225.82	11.47	198	28778	46459	50529689
Hallucination, visual	161.82	11.47	107	28869	16475	50559673
Gambling	154.10	11.47	34	28942	202	50575946
Parkinsonism hyperpyrexia syndrome	131	11.47	27	28949	109	50576039
Restless legs syndrome	123.14	11.47	89	28887	15808	50560340
Hypersexuality	112.73	11.47	30	28946	424	50575724
Tremor	111.77	11.47	220	28756	114683	50461465
Dystonia	111.64	11.47	75	28901	11851	50564297
Freezing phenomenon	96.87	11.47	32	28944	983	50575165
Pleurothotonus	92.87	11.47	33	28943	1268	50574880
Obsessive-compulsive disorder	92.79	11.47	43	28933	3297	50572851
Bradykinesia	91.94	11.47	45	28931	3898	50572250
Sudden onset of sleep	89.93	11.47	26	28950	506	50575642
Stoma site discharge	89.72	11.47	32	28944	1243	50574905
Stoma site erythema	88.69	11.47	29	28947	862	50575286
Muscle rigidity	85.32	11.47	59	28917	9770	50566378
Stereotypy	84.30	11.47	23	28953	359	50575789
Binge eating	74.28	11.47	21	28955	376	50575772
Stoma site pain	71.39	11.47	24	28952	779	50575369
Camptocormia	70.53	11.47	19	28957	282	50575866
Orthostatic hypotension	69.36	11.47	85	28891	29396	50546752
Systemic lupus erythematosus	67.75	11.47	3	28973	140619	50435529
Fall	65.48	11.47	370	28606	334562	50241586
Jealous delusion	63.16	11.47	12	28964	28	50576120
Hyperkinesia	54.20	11.47	23	28953	1429	50574719
Therapeutic response shortened	54.11	11.47	40	28936	7349	50568799
Compulsive hoarding	52.31	11.47	11	28965	50	50576098
Delusion	51.36	11.47	45	28931	10524	50565624
Drug dispensed to wrong patient	48.96	11.47	13	28963	182	50575966
Contraindicated product administered	47.93	11.47	13	28963	148945	50427203
Maternal exposure during pregnancy	47.69	11.47	16	28960	159762	50416386
Torticollis	47.14	11.47	22	28954	1714	50574434
Psychotic disorder	46.70	11.47	60	28916	21752	50554396
Diabetes mellitus inadequate control	46.64	11.47	47	28929	13098	50563050
Glossodynia	45.83	11.47	6	28970	115563	50460585
Synovitis	45.54	11.47	8	28968	123857	50452291
Acute psychosis	44.88	11.47	23	28953	2197	50573951
Medication error	43.67	11.47	76	28900	36028	50540120
Neuroleptic malignant syndrome	41.72	11.47	41	28935	11089	50565059
Somnolence	39.81	11.47	185	28791	154800	50421348
Abnormal dreams	39.81	11.47	37	28939	9340	50566808
Abnormal behaviour	38.86	11.47	52	28924	19606	50556542
Vestibular migraine	38.44	11.47	11	28965	206	50575942
Sleep attacks	37.82	11.47	9	28967	78	50576070
Akinesia	37.64	11.47	18	28958	1481	50574667
Joint swelling	36.92	11.47	52	28924	245234	50330914
Gait disturbance	36.30	11.47	176	28800	149829	50426319
Multiple drug therapy	36.09	11.47	19	28957	1918	50574230
Febrile neutropenia	34.42	11.47	7	28969	97660	50478488
Psychomotor hyperactivity	34.37	11.47	34	28942	9267	50566881
Pericarditis	33.96	11.47	3	28973	78686	50497462
Alopecia	33.00	11.47	56	28920	244991	50331157
Pituitary haemorrhage	32.50	11.47	8	28968	81	50576067
Hand deformity	31.74	11.47	9	28967	100190	50475958
Dopamine dysregulation syndrome	31.53	11.47	9	28967	167	50575981
Delirium	31.05	11.47	68	28908	38124	50538024
Malignant polyp	31.04	11.47	9	28967	177	50575971
Dependence	31.04	11.47	17	28959	1858	50574290
Dropped head syndrome	30.89	11.47	8	28968	101	50576047
Blood pressure inadequately controlled	30.48	11.47	23	28953	4357	50571791
Drug intolerance	29.56	11.47	50	28926	219054	50357094
Anxiety	29.34	11.47	188	28788	177418	50398730
Product prescribing error	29.18	11.47	47	28929	20914	50555234
Bronchopulmonary aspergillosis allergic	28.99	11.47	14	28962	1177	50574971
Memory impairment	28.45	11.47	105	28871	79255	50496893
Parkinsonism	28.44	11.47	30	28946	8817	50567331
Economic problem	28.25	11.47	16	28960	1866	50574282
Neutropenia	28.07	11.47	26	28950	147939	50428209
Total lung capacity decreased	27.92	11.47	14	28962	1277	50574871
Lung opacity	27.54	11.47	16	28960	1957	50574191
Treatment failure	27.54	11.47	23	28953	137614	50438534
Hypersensitivity	27.31	11.47	51	28925	215110	50361038
Stoma site infection	27.11	11.47	11	28965	610	50575538
Rash	26.97	11.47	144	28832	437327	50138821
Exercise tolerance decreased	26.22	11.47	22	28954	4852	50571296
Malignant neoplasm progression	25.92	11.47	4	28972	68120	50508028
Hyperphagia	25.66	11.47	14	28962	1518	50574630
Crime	25.41	11.47	5	28971	15	50576133
Orthostatic intolerance	25.34	11.47	12	28964	966	50575182
Fibroma	25.32	11.47	11	28965	724	50575424
Depressed mood	24.78	11.47	58	28918	33965	50542183
Amnesia	24.45	11.47	66	28910	42194	50533954
Discomfort	24.41	11.47	16	28960	108364	50467784
Hyperventilation	24.24	11.47	22	28954	5387	50570761
Posture abnormal	24.13	11.47	15	28961	2074	50574074
Deep brain stimulation	23.22	11.47	5	28971	26	50576122
Oedema peripheral	22.37	11.47	161	28815	157800	50418348
Abdominal discomfort	22.08	11.47	64	28912	231577	50344571
Vaccination site oedema	21.82	11.47	4	28972	7	50576141
Swelling	21.81	11.47	52	28924	200820	50375328
Chorea	21.77	11.47	12	28964	1328	50574820
Cognitive disorder	21.72	11.47	65	28911	44058	50532090
Compulsions	21.51	11.47	7	28969	205	50575943
Vaccination site bruising	21.47	11.47	4	28972	8	50576140
Vaccination site pruritus	21.47	11.47	4	28972	8	50576140
Withdrawal syndrome	21.23	11.47	37	28939	17553	50558595
Movement disorder	21.16	11.47	37	28939	17595	50558553
Sleep apnoea syndrome	21.13	11.47	44	28932	23824	50552324
Nightmare	20.95	11.47	35	28941	16051	50560097
Therapeutic response changed	20.91	11.47	10	28966	823	50575325
Female orgasmic disorder	20.28	11.47	5	28971	51	50576097
Insomnia	20.20	11.47	170	28806	174695	50401453
Heat stroke	20.14	11.47	9	28967	634	50575514
Infusion related reaction	19.95	11.47	42	28934	169515	50406633
Exposure during pregnancy	19.88	11.47	24	28952	120991	50455157
Snoring	19.72	11.47	16	28960	3368	50572780
Drug withdrawal syndrome	19.64	11.47	44	28932	25037	50551111
Coronary artery dissection	19.08	11.47	9	28967	718	50575430
Confusional state	19.02	11.47	176	28800	185752	50390396
Drug interaction	18.96	11.47	186	28790	199435	50376713
Diarrhoea	18.94	11.47	231	28745	588245	49987903
Serum serotonin increased	18.79	11.47	6	28970	165	50575983
Product residue present	18.58	11.47	16	28960	3656	50572492
Stoma site irritation	18.46	11.47	6	28970	175	50575973
Suspiciousness	18.43	11.47	7	28969	325	50575823
Inhibitory drug interaction	18.43	11.47	13	28963	2220	50573928
Restlessness	18.43	11.47	43	28933	25130	50551018
Therapeutic product effect variable	18.37	11.47	10	28966	1080	50575068
Orgasm abnormal	17.98	11.47	5	28971	84	50576064
Narcolepsy	17.78	11.47	10	28966	1150	50574998
Pre-existing condition improved	17.56	11.47	21	28955	7076	50569072
Product substitution issue	17.53	11.47	30	28946	14027	50562121
Parkinson's disease	17.51	11.47	10	28966	1185	50574963
Rheumatoid arthritis	17.16	11.47	59	28917	202491	50373657
Stoma site inflammation	17.05	11.47	7	28969	400	50575748
Meningorrhagia	16.89	11.47	5	28971	106	50576042
Pancytopenia	16.85	11.47	14	28962	84016	50492132
Bipolar disorder	16.73	11.47	20	28956	6737	50569411
Toxicity to various agents	16.61	11.47	64	28912	212435	50363713
Arthropathy	16.25	11.47	42	28934	157864	50418284
Blood calcium increased	16.15	11.47	21	28955	7698	50568450
Feeling abnormal	16.11	11.47	125	28851	125367	50450781
Product use issue	15.97	11.47	39	28937	149436	50426712
Stoma site hypergranulation	15.71	11.47	6	28970	283	50575865
Vaccination site erythema	15.56	11.47	4	28972	49	50576099
Autonomic nervous system imbalance	15.45	11.47	12	28964	2373	50573775
Hypercapnia	15.43	11.47	16	28960	4611	50571537
Off label use	15.33	11.47	186	28790	474240	50101908
Compulsive sexual behaviour	14.81	11.47	4	28972	60	50576088
Disease progression	14.72	11.47	20	28956	95846	50480302
Stomatitis	14.71	11.47	22	28954	101322	50474826
Aspiration	14.60	11.47	22	28954	9242	50566906
Dizziness	14.32	11.47	278	28698	346091	50230057
Stoma site candida	14.20	11.47	3	28973	14	50576134
Vitamin B6 deficiency	13.93	11.47	4	28972	76	50576072
Thrombocytopenia	13.89	11.47	33	28943	127640	50448508
Vaccination site pain	13.78	11.47	4	28972	79	50576069
Depression	13.73	11.47	150	28826	165273	50410875
Bulimia nervosa	13.72	11.47	6	28970	401	50575747
Stoma site reaction	13.67	11.47	5	28971	209	50575939
Speech disorder	13.55	11.47	48	28928	35500	50540648
Middle insomnia	13.47	11.47	22	28954	9899	50566249
Endometrial cancer	13.46	11.47	12	28964	2871	50573277
Muscle atrophy	13.35	11.47	17	28959	6104	50570044
Drug abuse	13.25	11.47	9	28967	59837	50516311
Choking	13.14	11.47	20	28956	8478	50567670
Balance disorder	13.07	11.47	77	28899	70513	50505635
Hepatic enzyme increased	13.04	11.47	38	28938	137342	50438806
Anisomastia	12.82	11.47	3	28973	24	50576124
Kleptomania	12.61	11.47	3	28973	26	50576122
Reduced facial expression	12.51	11.47	9	28967	1585	50574563
Tardive dyskinesia	12.51	11.47	18	28958	7261	50568887
Ill-defined disorder	12.39	11.47	8	28968	54646	50521502
Muscle injury	12.38	11.47	3	28973	37108	50539040
Mucosal inflammation	12.00	11.47	4	28972	40138	50536010
Suicidal ideation	11.97	11.47	63	28913	55322	50520826
Blister	11.96	11.47	19	28957	85399	50490749
Medical device site dryness	11.88	11.47	3	28973	34	50576114
Accidental overdose	11.80	11.47	31	28945	19502	50556646
Rheumatoid factor positive	11.72	11.47	7	28969	49852	50526296
Chronic obstructive pulmonary disease	11.70	11.47	61	28915	53374	50522774
Product administration error	11.63	11.47	31	28945	19668	50556480
Skull fracture	11.59	11.47	7	28969	919	50575229
Device kink	11.50	11.47	9	28967	1798	50574350

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Impulse-control disorder	724.53	14.22	166	18758	1059	29554544
Gambling disorder	607.04	14.22	151	18773	1424	29554179
Hypersexuality	573.08	14.22	140	18784	1216	29554387
Hallucination	416.77	14.22	292	18632	44420	29511183
Dyskinesia	322.21	14.22	185	18739	19876	29535727
On and off phenomenon	263.54	14.22	82	18842	1846	29553757
Dopamine dysregulation syndrome	223.79	14.22	50	18874	279	29555324
Gambling	196.34	14.22	41	18883	156	29555447
Hallucination, visual	187.88	14.22	118	18806	14897	29540706
Compulsive shopping	178.28	14.22	43	18881	351	29555252
Stereotypy	120.11	14.22	35	18889	624	29554979
Jealous delusion	116.33	14.22	27	18897	183	29555420
Obsessive-compulsive disorder	112.26	14.22	56	18868	4520	29551083
Freezing phenomenon	109.17	14.22	38	18886	1225	29554378
Delusion	105.95	14.22	74	18850	11142	29544461
Paraphilia	98.93	14.22	20	18904	62	29555541
Restless legs syndrome	92.66	14.22	57	18867	6927	29548676
Needle fatigue	88.24	14.22	27	18897	573	29555030
Gait disturbance	87.23	14.22	163	18761	73186	29482417
Gait spastic	84.52	14.22	27	18897	663	29554940
Muscle rigidity	84.04	14.22	60	18864	9351	29546252
Libido increased	83.36	14.22	27	18897	694	29554909
Relapsing-remitting multiple sclerosis	82.95	14.22	27	18897	705	29554898
Sudden onset of sleep	81.90	14.22	23	18901	357	29555246
Fall	80.96	14.22	273	18651	176905	29378698
Parkinsonism hyperpyrexia syndrome	80.14	14.22	17	18907	71	29555532
Bradykinesia	75.27	14.22	39	18885	3408	29552195
Abnormal behaviour	73.32	14.22	82	18842	23045	29532558
Stoma site erythema	70.29	14.22	23	18901	611	29554992
Psychomotor hyperactivity	70.21	14.22	51	18873	8162	29547441
Nocturia	69.39	14.22	51	18873	8311	29547292
Insomnia	69.15	14.22	166	18758	88595	29467008
Hypertonic bladder	64.85	14.22	27	18897	1429	29554174
Monoparesis	64.18	14.22	29	18895	1874	29553729
Memory impairment	63.25	14.22	96	18828	36374	29519229
Micturition urgency	63.02	14.22	40	18884	5133	29550470
Stoma site discharge	61.98	14.22	23	18901	894	29554709
Hyperkinesia	59.16	14.22	26	18898	1573	29554030
Movement disorder	56.20	14.22	49	18875	10188	29545415
Impulsive behaviour	54.31	14.22	26	18898	1917	29553686
Encephalitis toxic	51.23	14.22	15	18909	272	29555331
Toxicity to various agents	50.54	14.22	24	18900	173637	29381966
Binge eating	50.52	14.22	12	18912	91	29555512
Muscle spasticity	50.31	14.22	34	18890	4849	29550754
Agitation	50.05	14.22	105	18819	51199	29504404
Psychotic disorder	49.40	14.22	63	18861	20291	29535312
Balance disorder	48.82	14.22	85	18839	36085	29519518
Compulsive hoarding	48.76	14.22	9	18915	14	29555589
Central nervous system lesion	48.11	14.22	35	18889	5613	29549990
Confusional state	48.03	14.22	185	18739	127692	29427911
Dysarthria	47.52	14.22	77	18847	30834	29524769
Stoma site pain	46.34	14.22	16	18908	503	29555100
Tremor	46.32	14.22	127	18797	73411	29482192
Neuroleptic malignant syndrome	45.68	14.22	54	18870	16094	29539509
Aggression	44.72	14.22	81	18843	35460	29520143
Mania	44.63	14.22	40	18884	8623	29546980
Voyeurism	44.49	14.22	7	18917	0	29555603
Dependence	42.11	14.22	18	18906	1017	29554586
Anxiety	41.95	14.22	135	18789	85230	29470373
Sleep attacks	41.55	14.22	11	18913	135	29555468
Delirium	41.20	14.22	83	18841	39314	29516289
Compulsive sexual behaviour	40.56	14.22	12	18912	226	29555377
Febrile neutropenia	40.28	14.22	11	18913	112229	29443374
Neutropenia	40.18	14.22	17	18907	131694	29423909
Somnolence	39.49	14.22	141	18783	93814	29461789
Pyrexia	39.38	14.22	78	18846	287544	29268059
Hyperphagia	38.99	14.22	18	18906	1222	29554381
Dystonia	38.75	14.22	39	18885	9710	29545893
Economic problem	38.72	14.22	18	18906	1242	29554361
Ataxia	38.49	14.22	43	18881	12060	29543543
Hypomania	37.40	14.22	21	18903	2154	29553449
Posture abnormal	36.77	14.22	20	18904	1927	29553676
Acute kidney injury	36.25	14.22	72	18852	265195	29290408
Device dislocation	36.18	14.22	27	18897	4500	29551103
Diarrhoea	36.16	14.22	102	18822	332596	29223007
Multiple sclerosis relapse	35.34	14.22	40	18884	11379	29544224
Restlessness	35.17	14.22	56	18868	22089	29533514
Suspiciousness	33.48	14.22	11	18913	296	29555307
Dementia	32.99	14.22	39	18885	11619	29543984
Paranoia	32.98	14.22	36	18888	9841	29545762
Therapeutic product effect variable	31.94	14.22	18	18906	1859	29553744
Excessive masturbation	31.44	14.22	8	18916	83	29555520
Personality change	31.26	14.22	25	18899	4613	29550990
Sexually inappropriate behaviour	30.57	14.22	11	18913	391	29555212
Bipolar I disorder	30.46	14.22	13	18911	732	29554871
Road traffic accident	29.89	14.22	43	18881	15518	29540085
Platelet count decreased	29.60	14.22	15	18909	104657	29450946
Dizziness	28.96	14.22	214	18710	189470	29366133
Condition aggravated	28.91	14.22	176	18748	146119	29409484
Pollakiuria	28.56	14.22	44	18880	16872	29538731
Akinesia	28.34	14.22	17	18907	1973	29553630
Pancytopenia	28.27	14.22	9	18915	83159	29472444
Acute psychosis	28.22	14.22	16	18908	1671	29553932
Anticholinergic syndrome	28.18	14.22	13	18911	881	29554722
Dropped head syndrome	28.14	14.22	8	18916	130	29555473
Hypervigilance	28.08	14.22	8	18916	131	29555472
Reduced facial expression	27.81	14.22	12	18912	694	29554909
Embedded device	27.79	14.22	9	18915	231	29555372
Somnambulism	27.68	14.22	19	18905	2779	29552824
Obsessive-compulsive personality disorder	27.33	14.22	8	18916	145	29555458
Hallucination, tactile	26.43	14.22	9	18915	271	29555332
Sleep disorder	26.23	14.22	52	18872	24334	29531269
Parkinson's disease	25.76	14.22	14	18910	1347	29554256
Compulsions	25.62	14.22	8	18916	182	29555421
Delusional disorder, jealous type	25.42	14.22	4	18920	0	29555603
Depressive symptom	25.31	14.22	15	18909	1702	29553901
Cognitive disorder	25.15	14.22	50	18874	23449	29532154
Human ehrlichiosis	25.10	14.22	8	18916	195	29555408
Spontaneous penile erection	24.83	14.22	8	18916	202	29555401
Dysstasia	24.75	14.22	32	18892	10442	29545161
Contraindicated product prescribed	24.52	14.22	9	18915	339	29555264
Stoma site haemorrhage	24.41	14.22	11	18913	706	29554897
Disturbance in attention	23.42	14.22	46	18878	21378	29534225
Device occlusion	23.33	14.22	23	18901	5585	29550018
Depression	23.28	14.22	112	18812	85035	29470568
Drug withdrawal syndrome	22.62	14.22	41	18883	17943	29537660
Stoma site inflammation	22.61	14.22	9	18915	424	29555179
Stoma site hypergranulation	22.59	14.22	7	18917	155	29555448
Sleep-related eating disorder	22.41	14.22	8	18916	278	29555325
Inappropriate antidiuretic hormone secretion	22.16	14.22	31	18893	10901	29544702
Cardiac dysfunction	22.08	14.22	14	18910	1793	29553810
Withdrawal syndrome	22.03	14.22	31	18893	10961	29544642
Food interaction	22.03	14.22	11	18913	889	29554714
Sleep apnoea syndrome	21.98	14.22	40	18884	17559	29538044
Rapid eye movements sleep abnormal	21.83	14.22	7	18917	174	29555429
Verbal abuse	21.79	14.22	7	18917	175	29555428
Malignant neoplasm progression	21.77	14.22	10	18914	73849	29481754
Erectile dysfunction	21.33	14.22	40	18884	17969	29537634
Device issue	20.33	14.22	25	18899	7755	29547848
Parkinsonism	20.02	14.22	24	18900	7254	29548349
Bradycardia	19.90	14.22	89	18835	65540	29490063
White blood cell count decreased	19.35	14.22	15	18909	83347	29472256
Abnormal dreams	19.33	14.22	23	18901	6897	29548706
Sepsis	19.20	14.22	39	18885	142643	29412960
Motor dysfunction	18.73	14.22	21	18903	5909	29549694
Marital problem	18.69	14.22	5	18919	64	29555539
Nightmare	18.30	14.22	29	18895	11388	29544215
Suicidal ideation	18.02	14.22	56	18868	34660	29520943
Sexual activity increased	17.95	14.22	4	18920	22	29555581
Cardiac arrest	17.92	14.22	17	18907	85574	29470029
Eosinophilic fasciitis	17.90	14.22	5	18919	76	29555527
Sopor	17.84	14.22	28	18896	10906	29544697
Visual impairment	17.39	14.22	50	18874	29658	29525945
Torticollis	17.29	14.22	10	18914	1085	29554518
Gait inability	17.19	14.22	37	18887	18338	29537265
Lung hyperinflation	17.19	14.22	9	18915	803	29554800
Hyperkalaemia	17.05	14.22	9	18915	61383	29494220
Device kink	17	14.22	7	18917	360	29555243
Device effect decreased	16.99	14.22	3	18921	3	29555600
Intentional medical device removal by patient	16.93	14.22	6	18918	204	29555399
Device alarm issue	16.91	14.22	8	18916	574	29555029
Mobility decreased	16.68	14.22	45	18879	25735	29529868
Tension	16.62	14.22	12	18912	1901	29553702
Disease progression	16.31	14.22	17	18907	81899	29473704
Neutrophil count decreased	16.13	14.22	4	18920	43563	29512040
Rash	15.91	14.22	65	18859	189754	29365849
Mental impairment	15.74	14.22	24	18900	9117	29546486
Troponin increased	15.66	14.22	24	18900	9159	29546444
Stoma site infection	15.48	14.22	8	18916	695	29554908
Rapid eye movement sleep behaviour disorder	15.42	14.22	5	18919	129	29555474
Interstitial lung disease	15.25	14.22	9	18915	57709	29497894
Therapeutic response shortened	15.19	14.22	17	18907	4774	29550829
Paedophilia	15.17	14.22	3	18921	8	29555595
Excessive exercise	15.17	14.22	3	18921	8	29555595
Pleurothotonus	15.12	14.22	9	18915	1029	29554574
Micturition disorder	14.44	14.22	11	18913	1890	29553713
Anaemia	14.34	14.22	73	18851	200878	29354725
Ascites	14.28	14.22	3	18921	36616	29518987
IVth nerve paresis	14.24	14.22	3	18921	12	29555591

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Impulse-control disorder	719.08	11.43	170	37084	1418	64460060
Gambling disorder	599.38	11.43	152	37102	1742	64459736
Dyskinesia	526.20	11.43	311	36943	39077	64422401
Hallucination	422.35	11.43	344	36910	72444	64389034
Hypersexuality	391.60	11.43	103	37151	1376	64460102
On and off phenomenon	376.09	11.43	112	37142	2407	64459071
Hallucination, visual	276.09	11.43	182	37072	27652	64433826
Compulsive shopping	263.90	11.43	66	37188	711	64460767
Dopamine dysregulation syndrome	231.11	11.43	54	37200	425	64461053
Parkinsonism hyperpyrexia syndrome	211.48	11.43	44	37210	186	64461292
Gambling	184.85	11.43	41	37213	248	64461230
Jealous delusion	149.58	11.43	33	37221	194	64461284
Stereotypy	145.77	11.43	42	37212	800	64460678
Freezing phenomenon	136.25	11.43	46	37208	1500	64459978
Dystonia	134.90	11.43	101	37153	18764	64442714
Restless legs syndrome	129.95	11.43	95	37159	17021	64444457
Bradykinesia	129.31	11.43	67	37187	6493	64454985
Delusion	116.83	11.43	91	37163	17923	64443555
Fall	114.56	11.43	510	36744	416316	64045162
Muscle rigidity	110.58	11.43	87	37167	17386	64444092
Stoma site erythema	109.72	11.43	37	37217	1202	64460276
Obsessive-compulsive disorder	108.96	11.43	54	37200	4764	64456714
Stoma site discharge	102.32	11.43	38	37216	1644	64459834
Hyperkinesia	100.28	11.43	42	37212	2504	64458974
Tremor	96.44	11.43	243	37011	147987	64313491
Psychotic disorder	94.36	11.43	108	37146	34470	64427008
Binge eating	94.01	11.43	26	37228	424	64461054
Compulsive hoarding	91.06	11.43	18	37236	55	64461423
Neuroleptic malignant syndrome	91.05	11.43	91	37163	24905	64436573
Sudden onset of sleep	86.49	11.43	26	37228	577	64460901
Pleurothotonus	84.10	11.43	36	37218	2266	64459212
Needle fatigue	82.82	11.43	25	37229	563	64460915
Stoma site pain	81.61	11.43	29	37225	1104	64460374
Abnormal behaviour	80.13	11.43	98	37156	33524	64427954
Gait disturbance	77.47	11.43	247	37007	171908	64289570
Gait spastic	72.58	11.43	25	37229	867	64460611
Therapeutic response shortened	69.49	11.43	53	37201	10117	64451361
Acute psychosis	67.35	11.43	36	37218	3716	64457762
Relapsing-remitting multiple sclerosis	67.28	11.43	25	37229	1083	64460395
Torticollis	66.43	11.43	30	37224	2147	64459331
Akinesia	65.18	11.43	33	37221	3046	64458432
Orthostatic hypotension	64.70	11.43	105	37149	46633	64414845
Febrile neutropenia	63.84	11.43	15	37239	187642	64273836
Delirium	63.41	11.43	130	37124	69064	64392414
Paraphilia	63.05	11.43	13	37241	52	64461426
Camptocormia	61.56	11.43	19	37235	462	64461016
Insomnia	59.46	11.43	249	37005	197587	64263891
Sleep attacks	59.36	11.43	15	37239	169	64461309
Nocturia	58.88	11.43	50	37204	11115	64450363
Neutropenia	58.24	11.43	33	37221	239591	64221887
Movement disorder	55.48	11.43	66	37188	21934	64439544
Psychomotor hyperactivity	55.20	11.43	54	37200	14397	64447081
Impulsive behaviour	54.79	11.43	28	37226	2635	64458843
Toxicity to various agents	52.04	11.43	81	37173	363432	64098046
Anxiety	51.77	11.43	243	37011	202406	64259072
Therapeutic product effect variable	51.26	11.43	23	37231	1621	64459857
Dropped head syndrome	50.47	11.43	14	37240	231	64461247
Drug withdrawal syndrome	49.85	11.43	75	37179	31216	64430262
Monoparesis	49.45	11.43	27	37227	2907	64458571
Posture abnormal	48.33	11.43	28	37226	3378	64458100
Encephalitis toxic	48.08	11.43	14	37240	277	64461201
Suspiciousness	45.90	11.43	16	37238	575	64460903
Hypertonic bladder	45.61	11.43	27	37227	3391	64458087
Memory impairment	44.16	11.43	129	37125	85553	64375925
Micturition urgency	42.00	11.43	40	37214	10319	64451159
Cognitive disorder	41.89	11.43	96	37158	54991	64406487
Restlessness	41.57	11.43	79	37175	39706	64421772
Somnolence	41.36	11.43	229	37025	203416	64258062
Parkinsonism	41.08	11.43	46	37208	14327	64447151
Agitation	40.81	11.43	128	37126	88239	64373239
Pancytopenia	40.54	11.43	16	37238	143293	64318185
Drug dispensed to wrong patient	40.38	11.43	13	37241	364	64461114
Libido increased	40.29	11.43	20	37234	1770	64459708
Voyeurism	38.74	11.43	6	37248	0	64461478
Malignant neoplasm progression	38.42	11.43	9	37245	112862	64348616
Confusional state	38.23	11.43	270	36984	260874	64200604
Aggression	37.87	11.43	83	37171	46149	64415329
Economic problem	36.51	11.43	20	37234	2167	64459311
Rash	36.45	11.43	139	37115	458410	64003068
Hyperphagia	36.14	11.43	20	37234	2211	64459267
Medication error	35.72	11.43	85	37169	49881	64411597
Withdrawal syndrome	35.57	11.43	55	37199	23437	64438041
Multiple sclerosis relapse	35.01	11.43	75	37179	41060	64420418
Balance disorder	34.63	11.43	117	37137	83809	64377669
Depressive symptom	34.22	11.43	25	37229	4471	64457007
Central nervous system lesion	34.00	11.43	38	37216	11811	64449667
Pyrexia	33.91	11.43	187	37067	558457	63903021
Synovitis	33.53	11.43	8	37246	99082	64362396
Compulsions	33.29	11.43	11	37243	335	64461143
Nightmare	32.98	11.43	50	37204	20943	64440535
Abnormal dreams	32.83	11.43	35	37219	10321	64451157
Diarrhoea	32.79	11.43	264	36990	722440	63739038
Acute kidney injury	32.67	11.43	141	37113	449099	64012379
Reduced facial expression	31.67	11.43	18	37236	2095	64459383
Multiple drug therapy	30.58	11.43	18	37236	2236	64459242
Dementia	30.58	11.43	48	37206	20718	64440760
Mania	30.26	11.43	42	37212	16244	64445234
Condition aggravated	30.06	11.43	338	36916	372088	64089390
Dizziness	29.30	11.43	378	36876	429785	64031693
Contraindicated product administered	28.95	11.43	13	37241	107816	64353662
Depressed mood	28.49	11.43	69	37185	40943	64420535
Stoma site infection	28.39	11.43	14	37240	1221	64460257
Excessive masturbation	28.37	11.43	7	37247	71	64461407
Inappropriate antidiuretic hormone secretion	28.06	11.43	48	37206	22241	64439237
Malignant polyp	27.30	11.43	8	37246	162	64461316
Oedema peripheral	26.53	11.43	210	37044	210107	64251371
Sexually inappropriate behaviour	26.38	11.43	10	37244	458	64461020
Platelet count decreased	26.29	11.43	35	37219	167676	64293802
Blood pressure inadequately controlled	26.14	11.43	23	37231	5361	64456117
Dependence	26.11	11.43	16	37238	2139	64459339
Delusional disorder, jealous type	25.83	11.43	4	37250	0	64461478
Dysarthria	25.55	11.43	84	37170	59322	64402156
Personality change	25.41	11.43	28	37226	8565	64452913
Marital problem	25.23	11.43	8	37246	213	64461265
Sleep apnoea syndrome	24.93	11.43	54	37200	29778	64431700
Obsessive-compulsive personality disorder	24.82	11.43	7	37247	123	64461355
Bronchopulmonary aspergillosis allergic	24.80	11.43	14	37240	1608	64459870
Snoring	24.75	11.43	21	37233	4661	64456817
Compulsive sexual behaviour	24.26	11.43	8	37246	242	64461236
Erectile dysfunction	24.12	11.43	33	37221	12594	64448884
Total lung capacity decreased	24.02	11.43	14	37240	1708	64459770
Bipolar I disorder	23.66	11.43	14	37240	1757	64459721
Kleptomania	23.51	11.43	5	37249	24	64461454
Pericarditis	23.32	11.43	4	37250	62512	64398966
Diabetes mellitus inadequate control	23.09	11.43	43	37211	21278	64440200
Product prescribing error	23.08	11.43	58	37196	35211	64426267
Joint swelling	22.98	11.43	57	37197	215325	64246153
Pituitary haemorrhage	22.83	11.43	8	37246	292	64461186
Stomatitis	22.70	11.43	18	37236	109587	64351891
Hallucination, tactile	22.55	11.43	9	37245	474	64461004
Cardiac arrest	22.32	11.43	34	37220	154030	64307448
Orthostatic intolerance	22.30	11.43	13	37241	1587	64459891
Device occlusion	22.18	11.43	28	37226	9885	64451593
Maternal exposure during pregnancy	22.15	11.43	14	37240	95870	64365608
Chorea	22.09	11.43	14	37240	1986	64459492
Ataxia	22.02	11.43	43	37211	22041	64439437
Troponin increased	21.85	11.43	35	37219	15364	64446114
Vaccination site bruising	21.79	11.43	4	37250	7	64461471
Vaccination site oedema	21.44	11.43	4	37250	8	64461470
Vaccination site pruritus	21.44	11.43	4	37250	8	64461470
Hand deformity	21.36	11.43	5	37249	62766	64398712
Human ehrlichiosis	20.89	11.43	8	37246	377	64461101
Treatment failure	20.85	11.43	22	37232	116794	64344684
Pollakiuria	20.79	11.43	52	37202	31478	64430000
Autonomic nervous system imbalance	20.76	11.43	18	37236	4114	64457364
Spontaneous penile erection	20.74	11.43	6	37248	116	64461362
Food interaction	20.66	11.43	12	37242	1454	64460024
Paranoia	20.30	11.43	35	37219	16317	64445161
Product residue present	20.20	11.43	16	37238	3226	64458252
Rapid eye movements sleep abnormal	20.12	11.43	7	37247	250	64461228
Verbal abuse	19.94	11.43	7	37247	257	64461221
Drug intolerance	19.85	11.43	50	37204	187942	64273536
Muscle spasticity	19.81	11.43	35	37219	16634	64444844
Hyperventilation	19.73	11.43	22	37232	6818	64454660
Vestibular migraine	19.67	11.43	6	37248	140	64461338
Device dislocation	19.64	11.43	40	37214	21138	64440340
Hypomania	19.52	11.43	20	37234	5634	64455844
Hypervigilance	19.47	11.43	8	37246	454	64461024
Hypersensitivity	19.42	11.43	54	37200	196398	64265080
Mucosal inflammation	19.39	11.43	6	37248	62578	64398900
Dysstasia	19.37	11.43	42	37212	23173	64438305
Paedophilia	19.37	11.43	3	37251	0	64461478
Device kink	19.07	11.43	12	37242	1681	64459797
Glossodynia	18.66	11.43	7	37247	64689	64396789
Lung opacity	18.26	11.43	15	37239	3184	64458294
White blood cell count decreased	18.25	11.43	40	37214	157797	64303681
Product substitution issue	18.08	11.43	35	37219	17826	64443652
Therapeutic response unexpected	18.06	11.43	34	37220	16967	64444511
Bone marrow failure	18.04	11.43	3	37251	47949	64413529
Disease progression	18.00	11.43	34	37220	141646	64319832
Stoma site inflammation	17.80	11.43	8	37246	566	64460912
Thrombocytopenia	17.64	11.43	68	37186	223733	64237745
Disturbance in attention	17.59	11.43	58	37196	41016	64420462
Female orgasmic disorder	17.41	11.43	4	37250	29	64461449
Ascites	17.40	11.43	7	37247	61994	64399484
Urticaria	17.31	11.43	37	37217	147280	64314198
Stoma site hypergranulation	17.18	11.43	7	37247	389	64461089
Suicidal ideation	17.10	11.43	80	37174	66462	64395016
Hepatocellular injury	16.64	11.43	3	37251	45232	64416246
Drug hypersensitivity	16.43	11.43	76	37178	237739	64223739
Anticholinergic syndrome	16.26	11.43	13	37241	2656	64458822
Sleep disorder	16.25	11.43	73	37181	59636	64401842
Obsessive thoughts	16.15	11.43	9	37245	1008	64460470
Serum serotonin increased	15.89	11.43	6	37248	272	64461206
Discomfort	15.86	11.43	14	37240	80864	64380614
Device issue	15.61	11.43	38	37216	22610	64438868
Feeling abnormal	15.53	11.43	131	37123	133471	64328007
Prescribed underdose	15.50	11.43	33	37221	17982	64443496
Alanine aminotransferase increased	15.45	11.43	36	37218	138995	64322483
Drug reaction with eosinophilia and systemic symptoms	15.41	11.43	6	37248	54211	64407267
Hepatic function abnormal	15.40	11.43	9	37245	64304	64397174
Intentional medical device removal by patient	15.25	11.43	6	37248	304	64461174
Delusion of replacement	15.20	11.43	5	37249	150	64461328
Vaccination site erythema	15.16	11.43	4	37250	54	64461424
Choking	15.02	11.43	24	37230	10514	64450964
Contraindicated product prescribed	15	11.43	9	37245	1158	64460320
Stoma site candida	14.98	11.43	3	37251	10	64461468
Parkinson's disease	14.73	11.43	10	37244	1591	64459887
Hiccups	14.67	11.43	21	37233	8355	64453123
Cardiac dysfunction	14.54	11.43	13	37241	3093	64458385
Orgasm abnormal	14.53	11.43	5	37249	173	64461305
Exercise tolerance decreased	14.50	11.43	20	37234	7690	64453788
Off label use	14.48	11.43	268	36986	632538	63828940
Micturition disorder	14.39	11.43	13	37241	3135	64458343
Neutrophil count decreased	14.38	11.43	14	37240	77182	64384296
Blood calcium increased	14.35	11.43	21	37233	8521	64452957
Coronary artery dissection	14.31	11.43	8	37246	902	64460576
Rheumatoid arthritis	14.21	11.43	48	37206	164246	64297232
Alopecia	13.93	11.43	49	37205	165641	64295837
Vaccination site pain	13.79	11.43	4	37250	78	64461400
Eosinophilic fasciitis	13.76	11.43	5	37249	203	64461275
Arthropathy	13.70	11.43	31	37223	120936	64340542
Blister	13.62	11.43	16	37238	80951	64380527
Infusion related reaction	13.59	11.43	49	37205	164418	64297060
Stoma site irritation	13.56	11.43	5	37249	212	64461266
Sleep-related eating disorder	13.54	11.43	7	37247	675	64460803
Hypersomnia	13.50	11.43	33	37221	19684	64441794
Fibroma	13.47	11.43	7	37247	682	64460796
Underdose	13.40	11.43	39	37215	25790	64435688
Nasopharyngitis	13.34	11.43	63	37191	196010	64265468
Depression	13.26	11.43	163	37091	183128	64278350
Heat stroke	13.18	11.43	9	37245	1446	64460032
Amnesia	13.12	11.43	59	37195	48210	64413268
Speech disorder	13.01	11.43	59	37195	48382	64413096
Inhibitory drug interaction	12.83	11.43	13	37241	3614	64457864
Interstitial lung disease	12.81	11.43	23	37231	97709	64363769
Anisomastia	12.79	11.43	3	37251	24	64461454
Middle insomnia	12.75	11.43	25	37229	12852	64448626
Abdominal discomfort	12.74	11.43	58	37196	182264	64279214
Sexual activity increased	12.69	11.43	3	37251	25	64461453
Irritable bowel syndrome	12.67	11.43	3	37251	37366	64424112
Apathy	12.60	11.43	23	37231	11209	64450269
Excessive exercise	12.48	11.43	3	37251	27	64461451
Bladder sphincter atony	12.46	11.43	4	37250	111	64461367
Irritability	12.41	11.43	48	37206	36698	64424780
Motor dysfunction	12.40	11.43	23	37231	11350	64450128
Sepsis	12.39	11.43	80	37174	230261	64231217
Meningorrhagia	12.37	11.43	5	37249	272	64461206
Lung hyperinflation	12.35	11.43	9	37245	1603	64459875
Stoma site haemorrhage	12.35	11.43	9	37245	1604	64459874
Somnambulism	12.27	11.43	15	37239	5126	64456352
Euphoric mood	12.25	11.43	17	37237	6574	64454904
Mobility decreased	12.09	11.43	88	37166	85752	64375726
Hepatotoxicity	12.08	11.43	4	37250	39958	64421520
Stoma site extravasation	12.00	11.43	5	37249	294	64461184
Road traffic accident	11.92	11.43	42	37212	30703	64430775
Sopor	11.92	11.43	41	37213	29620	64431858
Hepatic enzyme increased	11.90	11.43	37	37217	129906	64331572
Device connection issue	11.88	11.43	7	37247	872	64460606

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N04BC05	NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Dopamine agonists
FDA MoA	N0000000117	Dopamine Agonists
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000975	Antioxidants
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018491	Dopamine Agonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D020011	Protective Agents
CHEBI has role	CHEBI:48407	antiparkinson agent
CHEBI has role	CHEBI:48578	free radical scavengers
CHEBI has role	CHEBI:51065	Dopamine receptor agonist
CHEBI has role	CHEBI:66956	antidyskinetic agent
FDA EPC	N0000175768	Nonergot Dopamine Agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Restless legs	indication	32914008	DOID:0050425
Parkinson's disease	indication	49049000	DOID:14330
Fibromyalgia	off-label use	203082005	DOID:631
Hallucinations	contraindication	7011001
Dyskinesia	contraindication	9748009
Orthostatic hypotension	contraindication	28651003
Narcolepsy	contraindication	60380001	DOID:8986
Psychotic disorder	contraindication	69322001
Sleep apnea	contraindication	73430006	DOID:0050847
Kidney disease	contraindication	90708001	DOID:557
Drowsy	contraindication	271782001
Malignant melanoma	contraindication	372244006
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.57	Basic
pKa2	5.18	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
0.375MG	MIRAPEX ER	BOEHRINGER INGELHEIM	N022421	Feb. 19, 2010	RX	TABLET, EXTENDED RELEASE	ORAL	8679533	Sept. 8, 2029	TREATMENT OF PARKINSONS DISEASE
0.75MG	MIRAPEX ER	BOEHRINGER INGELHEIM	N022421	Feb. 19, 2010	RX	TABLET, EXTENDED RELEASE	ORAL	8679533	Sept. 8, 2029	TREATMENT OF PARKINSONS DISEASE
1.5MG	MIRAPEX ER	BOEHRINGER INGELHEIM	N022421	Feb. 19, 2010	RX	TABLET, EXTENDED RELEASE	ORAL	8679533	Sept. 8, 2029	TREATMENT OF PARKINSONS DISEASE
2.25MG	MIRAPEX ER	BOEHRINGER INGELHEIM	N022421	June 17, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	8679533	Sept. 8, 2029	TREATMENT OF PARKINSONS DISEASE
3.75MG	MIRAPEX ER	BOEHRINGER INGELHEIM	N022421	June 17, 2011	RX	TABLET, EXTENDED RELEASE	ORAL	8679533	Sept. 8, 2029	TREATMENT OF PARKINSONS DISEASE
3MG	MIRAPEX ER	BOEHRINGER INGELHEIM	N022421	Feb. 19, 2010	RX	TABLET, EXTENDED RELEASE	ORAL	8679533	Sept. 8, 2029	TREATMENT OF PARKINSONS DISEASE
4.5MG	MIRAPEX ER	BOEHRINGER INGELHEIM	N022421	Feb. 19, 2010	RX	TABLET, EXTENDED RELEASE	ORAL	8679533	Sept. 8, 2029	TREATMENT OF PARKINSONS DISEASE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	AGONIST	EC50	6.60	WOMBAT-PK	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	4	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	7.12	PDSP
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.16	WOMBAT-PK
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		EC50	5.93	CHEMBL
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	5.93	PDSP
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.20	WOMBAT-PK
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	AGONIST	EC50	8.67	WOMBAT-PK
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.57	PDSP
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	5.46	PDSP
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	5.78	PDSP
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.28	PDSP
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	AGONIST	Ki	9.31	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	8.51	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_BOVIN		Kd	8.80	CHEMBL
D(3) dopamine receptor	GPCR		DRD3_RAT		Ki	9.35	CHEMBL

External reference:

ID	Source
4024071	VUID
N0000022076	NUI
D00559	KEGG_DRUG
191217-81-9	SECONDARY_CAS_RN
4021042	VANDF
4024071	VANDF
C0074710	UMLSCUI
CHEBI:8356	CHEBI
G6L	PDB_CHEM_ID
CHEMBL301265	ChEMBL_ID
DB00413	DRUGBANK_ID
CHEMBL3182733	ChEMBL_ID
CHEMBL542257	ChEMBL_ID
D000077487	MESH_DESCRIPTOR_UI
119570	PUBCHEM_CID
6227	INN_ID
953	IUPHAR_LIGAND_ID
83619PEU5T	UNII
236747	RXNORM
169631	MMSL
23370	MMSL
5340	MMSL
d04145	MMSL
006721	NDDF
006722	NDDF
108471007	SNOMEDCT_US
386852009	SNOMEDCT_US
412282004	SNOMEDCT_US
725650009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Mirapex ER	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0109	TABLET, EXTENDED RELEASE	0.38 mg	ORAL	NDA	32 sections
Mirapex ER	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0113	TABLET, EXTENDED RELEASE	1.50 mg	ORAL	NDA	32 sections
Mirapex ER	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0115	TABLET, EXTENDED RELEASE	3 mg	ORAL	NDA	32 sections
Mirapex ER	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0116	TABLET, EXTENDED RELEASE	4.50 mg	ORAL	NDA	32 sections
Mirapex ER	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0285	TABLET, EXTENDED RELEASE	0.75 mg	ORAL	NDA	32 sections
Mirapex ER	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0286	TABLET, EXTENDED RELEASE	2.25 mg	ORAL	NDA	32 sections
Mirapex ER	HUMAN PRESCRIPTION DRUG LABEL	1	0597-0287	TABLET, EXTENDED RELEASE	3.75 mg	ORAL	NDA	32 sections
Pramipexole Dihydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7597	TABLET	1 mg	ORAL	ANDA	28 sections
Pramipexole Dihydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6704	TABLET	0.25 mg	ORAL	ANDA	20 sections
Pramipexole Dihydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6704	TABLET	0.25 mg	ORAL	ANDA	20 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-251	TABLET, EXTENDED RELEASE	0.38 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-251	TABLET, EXTENDED RELEASE	0.38 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-252	TABLET, EXTENDED RELEASE	0.75 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-252	TABLET, EXTENDED RELEASE	0.75 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-253	TABLET, EXTENDED RELEASE	1.50 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-253	TABLET, EXTENDED RELEASE	1.50 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-254	TABLET, EXTENDED RELEASE	3 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-254	TABLET, EXTENDED RELEASE	3 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-255	TABLET, EXTENDED RELEASE	4.50 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-255	TABLET, EXTENDED RELEASE	4.50 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-305	TABLET, EXTENDED RELEASE	2.25 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-305	TABLET, EXTENDED RELEASE	2.25 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-306	TABLET, EXTENDED RELEASE	3.75 mg	ORAL	ANDA	28 sections
Pramipexole DihydrochlorideExtended-Release	HUMAN PRESCRIPTION DRUG LABEL	1	10370-306	TABLET, EXTENDED RELEASE	3.75 mg	ORAL	ANDA	28 sections
Pramipexole Dihydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-091	TABLET	0.13 mg	ORAL	ANDA	20 sections
Pramipexole Dihydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-091	TABLET	0.13 mg	ORAL	ANDA	20 sections
Pramipexole Dihydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-092	TABLET	0.25 mg	ORAL	ANDA	20 sections
Pramipexole Dihydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-092	TABLET	0.25 mg	ORAL	ANDA	20 sections
Pramipexole Dihydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-093	TABLET	0.50 mg	ORAL	ANDA	20 sections
Pramipexole Dihydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-093	TABLET	0.50 mg	ORAL	ANDA	20 sections